Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Exonuclease 3'-5' domain containing 3 (EXD3) is a protein-coding human gene that encodes an enzyme with predicted and experimentally supported 3'-5' exoribonuclease activity. EXD3 is required for 3'-end processing of certain microRNAs (AGO1-bound miRNAs), contributes to nucleic acid (DNA and RNA) metabolism, and has metal ion binding capability[1][3][4]. Its up-regulation is associated with increased risk and poorer prognosis in gastric cancer, suggesting a possible role in DNA damage repair and nucleotide metabolism, and making it a proposed candidate for prognostic cancer biomarker development[1][6]. There are currently no approved drugs targeting EXD3 directly, and its precise roles in other disease processes (e.g., thyroid hormone resistance) are not yet clearly characterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Exonuclease 3'-5' domain containing 3 (EXD3).